Prevention of Recurrent Miscarriage for Women with Antiphospholipid Antibody or Lupus Anticoagulant

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2005 Apr 23

PMID 15846641

Citations 89

Authors

M Empson

M Lassere

J Craig

J Scott

Affiliations

Soon will be listed here.

Abstract

Background: A range of treatments have been proposed to improve pregnancy outcome in recurrent pregnancy loss associated with antiphospholipid antibody (APL). Small studies have not resolved uncertainty about benefits and risks.

Objectives: To examine outcomes of all treatments given to maintain pregnancy in women with prior miscarriage and APL.

Search Strategy: We searched the Pregnancy and Childbirth Group's Trials Register (30 May 2004), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2003), MEDLINE (1966 to June 2003), EMBASE (1988 to June 2003), Lupus (volume one to eight, 1991 to 1999) and conference proceedings from the International Symposium on APL up to 1999.

Selection Criteria: Randomised or quasi-randomised, controlled trials of interventions in pregnant women with a history of pregnancy loss and APL.

Data Collection And Analysis: Two review authors independently assessed quality and extracted data for studies up to December 1999. One review author performed this for studies after 1999.

Main Results: Thirteen studies were found (849 participants). The quality was not high; 50% had clear evidence of allocation concealment. Participant characteristics varied between trials. Unfractionated heparin combined with aspirin (two trials; n = 140) significantly reduced pregnancy loss compared to aspirin alone (relative risk (RR) 0.46, 95% confidence interval (CI) 0.29 to 0.71). Low molecular weight heparin (LMWH) combined with aspirin compared to aspirin (one trial; n = 98) did not significantly reduce pregnancy loss (RR 0.78, 95% CI 0.39 to 1.57). There was no advantage in high-dose, over low-dose, unfractionated heparin (one trial; n = 50). Three trials of aspirin alone (n = 135) showed no significant reduction in pregnancy loss (RR 1.05, 95% CI 0.66 to 1.68). Prednisone and aspirin (three trials; n = 286) resulted in a significant increase in prematurity when compared to placebo, aspirin, and heparin combined with aspirin, and an increase in gestational diabetes, but no significant benefit. Intravenous immunoglobulin +/- unfractionated heparin and aspirin (two trials; n = 58) was associated with an increased risk of pregnancy loss or premature birth when compared to unfractionated heparin or LMWH combined with aspirin (RR 2.51, 95% CI 1.27 to 4.95). When compared to prednisone and aspirin, intravenous immunoglobulin (one trial; n = 82) was not significantly different in outcomes.

Authors' Conclusions: Combined unfractionated heparin and aspirin may reduce pregnancy loss by 54%. Large, randomised controlled trials with adequate allocation concealment are needed to explore potential differences between unfractionated heparin and LMWH.

Citing Articles

Reproductive factors and subsequent pregnancy outcomes in patients with prior pregnancy loss.

Yang X, Mu F, Zhang J, Yuan L, Zhang W, Yang Y BMC Pregnancy Childbirth. 2024; 24(1):219.

PMID: 38528474 PMC: 10964557. DOI: 10.1186/s12884-024-06422-1.

The Diagnostics and Treatment of Recurrent Pregnancy Loss.

Tomkiewicz J, Darmochwal-Kolarz D J Clin Med. 2023; 12(14).

PMID: 37510883 PMC: 10380966. DOI: 10.3390/jcm12144768.

Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/050, May 2022).

Toth B, Bohlmann M, Hancke K, Kuon R, Nawroth F, von Otte S Geburtshilfe Frauenheilkd. 2023; 83(1):49-78.

PMID: 37415921 PMC: 10321417. DOI: 10.1055/a-1895-9940.

Data-Driven Medicine in the Diagnosis and Treatment of Infertility.

de Santiago I, Polanski L J Clin Med. 2022; 11(21).

PMID: 36362653 PMC: 9654112. DOI: 10.3390/jcm11216426.

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

Russell M, Dey M, Flint J, Davie P, Allen A, Crossley A Rheumatology (Oxford). 2022; 62(4):e48-e88.

PMID: 36318966 PMC: 10070073. DOI: 10.1093/rheumatology/keac551.

References

Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998; 114(5 Suppl):489S-510S. DOI: 10.1378/chest.114.5_supplement.489s. View

Lockwood C, Romero R, Feinberg R, Clyne L, Coster B, Hobbins J . The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989; 161(2):369-73. DOI: 10.1016/0002-9378(89)90522-x. View

Silver R, MacGregor S, Sholl J, Hobart J, Neerhof M, Ragin A . Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993; 169(6):1411-7. DOI: 10.1016/0002-9378(93)90410-k. View

Sammaritano L . Update on the management of the pregnant patient with antiphospholipid antibody. Curr Rheumatol Rep. 2001; 3(3):213-21. DOI: 10.1007/s11926-001-0021-6. View

Farquharson R, Quenby S, Greaves M . Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002; 100(3):408-13. DOI: 10.1016/s0029-7844(02)02165-8. View

Pattison N, Chamley L, Birdsall M, Zanderigo A, LIDDELL H, McDougall J . Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000; 183(4):1008-12. DOI: 10.1067/mob.2000.106754. View

Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A . Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod. 1997; 12(9):2061-5. DOI: 10.1093/humrep/12.9.2061. View

Reece E, Garofalo J, Zheng X, Assimakopoulos E . Pregnancy outcome. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment. J Reprod Med. 1997; 42(1):49-55. View

PASSALEVA A, Massai G, DElios M, Livi C, Abbate R . Prevention of miscarriage in antiphospholipid syndrome. Autoimmunity. 1992; 14(2):121-5. DOI: 10.3109/08916939209083130. View

10.

Lubbe W, Butler W, Palmer S, Liggins G . Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983; 1(8338):1361-3. DOI: 10.1016/s0140-6736(83)92141-4. View

11.

Cohen H . Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Ann Med Interne (Paris). 1996; 147 Suppl 1:44. View

12.

FRANKLIN R, Kutteh W . Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod. 2002; 17(11):2981-5. DOI: 10.1093/humrep/17.11.2981. View

13.

Ogasawara M, Sasa H, Katano K, Aoyama T, Aoki K, Suzumori K . Recurrent abortion and moderate or strong antiphospholipid antibody production. Int J Gynaecol Obstet. 1998; 62(2):183-8. DOI: 10.1016/s0020-7292(98)00099-x. View

14.

Boda Z, Laszlo P, Pfliegler G, Tornai I, Rejto L, Schlammadinger A . Low molecular weight heparin as thromboprophylaxis throughout pregnancy in heritable thrombophilic women. Clin Appl Thromb Hemost. 2000; 5(3):198-9. View

15.

Takakuwa K, Arakawa M, Honda K, Imai T, Tamura M, Kurabayashi T . Immunosuppressive therapy for recurrent aborters with positive antiphospholipid antibodies and alteration of 6ketoPGF1 alpha/TXB2 ratio. J Perinat Med. 1997; 25(6):509-11. DOI: 10.1515/jpme.1997.25.6.509. View

16.

Sher G, Matzner W, Feinman M, Maassarani G, Zouves C, Chong P . The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol. 1998; 40(2):74-82. DOI: 10.1111/j.1600-0897.1998.tb00394.x. View

17.

Hasegawa I, Takakuwa K, Goto S, Yamada K, Sekizuka N, Kanazawa K . Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody. Hum Reprod. 1992; 7(2):203-7. DOI: 10.1093/oxfordjournals.humrep.a137617. View

18.

Mazzucconi M, Dragoni F, Chistolini A, Peraino M, Paesano R, Di Prima M . Efficacy of low dose prednisone plus aspirin in preventing spontaneous abortions and/or fetal deaths due to antiphospholipid antibodies: results of a pilot study. Autoimmunity. 1996; 24(2):123-5. DOI: 10.3109/08916939609001953. View

19.

LAURELL A, Nilsson I . Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases. J Lab Clin Med. 1957; 49(5):694-707. View

20.

Yasuda M, Takakuwa K, Tokunaga A, Tanaka K . Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995; 86(4 Pt 1):555-9. DOI: 10.1016/0029-7844(95)00247-o. View